{{.infobox .infobox-gene}}
| Symbol | SLC22A1 |
| Full Name | Solute Carrier Family 22 Member 1 (OCT1) |
| Protein Name | Organic Cation Transporter 1 |
| Chromosome | 11q13.4 |
| NCBI Gene ID | 6579 |
| OMIM | 607607 |
| Ensembl ID | ENSG00000175084 |
| UniProt ID | O15245 |
| Protein Size | 554 amino acids |
| Molecular Weight | ~61 kDa |
| Associated Diseases | Parkinson's Disease, Alzheimer's Disease, Drug Transport at BBB |
Organic cation transporter 1 (OCT1). Mediates uptake of organic cations including neurotransmitters and drugs. Important for hepatic drug clearance. May transport neurotoxic compounds.
The SLC22A1 gene is located on chromosome 11q13.4 and consists of 12 exons spanning approximately 27 kb of genomic DNA. The gene encodes a polytopic membrane protein with 12 predicted transmembrane domains, characteristic of the major facilitator superfamily (MFS). The promoter region contains binding sites for hepatocyte nuclear factors (HNFs) and other tissue-specific transcription factors, explaining its high expression in liver and kidney. [@koepsell2007]
| Property | Value |
|---|---|
| Chromosome | 11q13.4 |
| Genomic Size | ~27 kb |
| Exon Count | 12 |
| Protein Length | 554 amino acids |
| Molecular Weight | ~61 kDa |
| Transmembrane Domains | 12 |
OCT1 contains characteristic features of MFS transporters:
The transport mechanism involves an alternating access model where the substrate binding site alternates between outward-facing and inward-facing conformations. [@nies2020]
OCT1 is expressed at the blood-brain barrier (BBB) on the luminal (blood-facing) membrane of brain microvascular endothelial cells. This strategic localization enables:
[@kekuda2019]
Expression levels vary across brain regions, with highest expression in:
The BBB expresses multiple organic cation transporters (OCT1, OCT2, OCT3, MATEs) that collectively determine CNS penetration of cationic drugs:
| Transporter | Location | Primary Function |
|---|---|---|
| OCT1 | Luminal membrane | Drug uptake into brain |
| OCT2 | Luminal membrane | Similar to OCT1 |
| OCT3 | Abluminal membrane | Organic cation efflux |
| MATEs | Luminal membrane | Drug efflux into blood |
[@bacher2021]
OCT1 can transport dopamine, a key neurotransmitter lost in Parkinson's disease. At the BBB, OCT1-mediated transport may influence:
OCT1 plays a significant role in Parkinson's disease pharmacotherapy:
[@wessler2018]
The potential for OCT1 to transport neurotoxic compounds is concerning:
OCT1 can transport choline, a precursor for acetylcholine synthesis. In Alzheimer's disease:
[@gibert2019]
OCT1 significantly impacts CNS delivery of Alzheimer's drugs:
| Drug Class | OCT1 Transport | Clinical Impact |
|---|---|---|
| Cholinesterase inhibitors | Yes | Alters brain exposure |
| NMDA receptor antagonists | Partial | Contributes to efficacy |
| Aβ-targeting antibodies | No | Not relevant |
AD pathology affects BBB integrity and transporter expression:
SLC22A1 polymorphisms significantly impact drug response:
| Variant | Function | Clinical Effect |
|---|---|---|
| R61C | Loss-of-function | Reduced drug transport |
| P341L | Reduced activity | Altered pharmacokinetics |
| G401S | Normal function | No change |
| V501F | Variable | Substrate-dependent |
[@dos2021]
Key drug interactions affected by OCT1 genotype:
OCT1 genotyping is increasingly relevant for personalized medicine:
Multiple drugs affect OCT1 function:
| Interaction Type | Examples | Effect |
|---|---|---|
| Substrates | Metformin, morphine, dopamine | Transported by OCT1 |
| Inhibitors | Cimetidine, quinine | Reduce transport |
| Inducers | Rifampin | Increase expression |
OCT1 exhibits polyspecificity, transporting diverse cations:
Targeting OCT1 for CNS drug delivery:
| Approach | Mechanism | Development Stage |
|---|---|---|
| OCT1 agonists | Increase drug uptake | Preclinical |
| OCT1 inhibitors | Reduce neurotoxicity | Discovery |
| Gene therapy | Modulate expression | Preclinical |
[@nies2020]
OCT1 genotyping can guide therapy:
OCT1 belongs to the SLC22 family of organic cation transporters:
| Gene | Protein | Tissue Distribution |
|---|---|---|
| SLC22A1 | OCT1 | Liver, kidney, BBB |
| SLC22A2 | OCT2 | Kidney, brain |
| SLC22A3 | OCT3 | Heart, brain, placenta |
| SLC22A4 | OCTN1 | Kidney, heart |
| SLC22A5 | OCTN2 | Kidney, brain |
OCT1 operates in coordination with other transporters:
OCT1 expression may serve as a biomarker:
SLC22A1 encodes OCT1, a polyspecific organic cation transporter with critical roles in drug delivery to the brain. At the blood-brain barrier, OCT1 facilitates uptake of numerous pharmaceuticals, including Parkinson's disease medications like levodopa. Genetic variants of SLC22A1 significantly impact drug response, making it important for personalized medicine. While primarily expressed in liver and kidney, OCT1's presence at the BBB makes it particularly relevant for neurodegenerative disease therapy, where it influences both drug delivery and potential neurotoxin exposure.
OCT1 plays a major role in hepatic drug uptake and metabolism. The liver is the primary site for drug metabolism, and OCT1 facilitates the entry of cationic drugs into hepatocytes where they can be metabolized by cytochrome P450 enzymes and other metabolic pathways. This function is critical for the first-pass metabolism of many orally administered drugs. [@jonker2001]
Key aspects of OCT1-mediated hepatic uptake include:
[@peacock2018]
One of the most clinically significant substrates of OCT1 is metformin, the first-line treatment for type 2 diabetes. OCT1-mediated hepatic uptake of metformin is essential for its glucose-lowering effects. The transport kinetics of metformin via OCT1 determine the drug's efficacy and duration of action. [@gal是可2004]
Genetic variants in SLC22A1 that reduce OCT1 function can lead to:
[@ayka2016]
OCT1 can mediate the hepatic uptake of potentially hepatotoxic compounds. Some drugs cause liver injury through OCT1-mediated uptake into hepatocytes, where they may cause:
[@zhong2020]
Understanding OCT1's role in drug-induced liver injury helps predict which patients may be at risk and guides the development of safer therapeutic agents.
The blood-brain barrier (BBB) expresses organic cation transporters that significantly impact CNS drug delivery. OCT1 is strategically positioned on the luminal (blood-facing) side of brain microvascular endothelial cells, where it can mediate the uptake of organic cations into the brain. [@cecchelli2014]
The BBB expresses multiple organic cation transporters with distinct polarities:
| Transporter | Location | Direction | Significance |
|---|---|---|---|
| OCT1 | Luminal | Blood→Brain | Initial uptake |
| OCT2 | Luminal | Blood→Brain | Similar to OCT1 |
| OCT3 | Abluminal | Brain→Blood | Efflux |
| MATE1 | Luminal | Brain→Blood | Efflux |
[@abbott2010]
The rate of drug transport across the BBB via OCT1 depends on several factors:
[@watanabe2021]
Understanding OCT1's role at the BBB enables strategic drug development:
[@uchida2018]
SLC22A1 exhibits significant genetic variation that affects drug response:
| rs Number | Protein Change | Frequency | Functional Effect |
|---|---|---|---|
| rs12239046 | R61C | ~5-10% | Reduced transport |
| rs34130495 | P341L | ~2-5% | Decreased activity |
| rs35599694 | G401S | ~3-8% | Normal function |
| rs59234583 | V501F | ~1-3% | Variable |
[@dos2021]
Genetic variants in SLC22A1 significantly impact the pharmacokinetics and pharmacodynamics of many drugs:
Antidiabetic Drugs:
Antipsychotics:
Anticancer Agents:
[@staud2013]
Testing for SLC22A1 variants can guide therapy:
[@choudhury2007]
OCT1 expression in tumors can affect chemotherapy efficacy:
[@smith2014]
Changes in OCT1 expression can contribute to drug resistance:
[@staud2013]
OCT1 belongs to the major facilitator superfamily (MFS) with characteristic features:
The transporter alternates between outward-facing and inward-facing conformations to move substrates across the membrane. [@koepsell2007]
OCT1 exhibits broad substrate specificity:
The transport cycle involves:
SLC22A1 variants and expression changes may influence neurodegenerative disease:
Parkinson's Disease:
Alzheimer's Disease:
OCT1 plays a well-established role in metabolic disease:
Researchers use various systems to study OCT1:
Mouse models provide insights into OCT1 function:
[@jonker2001]
Studies of OCT1 function employ:
OCT1 genotyping enables precision medicine approaches:
Drug development strategies targeting OCT1:
Emerging approaches include:
OCT1 transports various endogenous compounds:
OCT1 handles numerous foreign compounds:
Monitoring OCT1 activity involves:
OCT1 expression may serve as: